Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
Iuliana Vaxman, Shaji Kumar, Francis K. Buadi, Martha Q. Lacy, David Dingli, Suzanne R. Hayman, Taxiarchis Kourelis, Rahma Warsame, Yi L. Hwa, Amie Fonder, MST Hobbs, Eli Muchtar, Nelson Leung, Prashant Kapoor, Ronald S. Go, Yi Lin, Wilson I. Gonsalves, Mustaqeem Siddiqui, Robert A. Kyle, S. Vincent Rajkumar, Morie A. Gertz, Angela Dispenzieri
Abstract
POEMS (Polyneuropathy, Organomegaly, Endocrinopathies, Monoclonal protein, Skin changes) syndrome is a rare paraneoplastic syndrome related to plasma cell disorders. The diagnosis is often delayed, and many patients are diagnosed and treated for chronic inflammatory demyelinating polyradiculopathy (CIDP) before the correct diagnosis of POEMS is made. Since the clinical manifestations of POEMS are debilitating with progressively deteriorating neurological symptoms, endocrine manifestations, and anasarca, early diagnosis and intervention are of paramount importance.